Bryan Giraudo is a Managing Director in San Francisco, responsible for the Firm’s Western North America biotechnology and medical technology relationships. With nearly twenty years of experience, Bryan has executed more than 100 initial public offerings, follow-on and convertible financing transactions, as well as product and company buy-side, sell-side and corporate collaboration strategic advisory assignments for biotechnology, specialty pharmaceutical and medical technology clients. Recent transactions include financings for Seattle Genetics, Theravance Biopharma, Alder Biopharmaceuticals, Retrophin and Xencor, as well as the sale of Raptor Pharmaceuticals to Horizon Pharma, Ambit Biosciences to Daiichi Sankyo, Ventana Medical System’s hostile defense and subsequent sale to Roche and the sale of Cougar Biotechnology to Johnson & Johnson.
Bryan received his B.A. from Georgetown University and resides in San Francisco with his family.